AstraZeneca's Imfinzi (durvalumab) plus chemotherapy combo has ... The decision is supported by the outcomes from the AEGEAN trial. AstraZeneca oncology haematology research and development ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone AstraZeneca's Imfinzi (durvalumab ...

Approval based on AEGEAN Phase III trial results which showed a 32% reduction in the risk of recurrence, progression or death vs. neoadjuvant chemotherapy alone AstraZeneca's Imfinzi (durvalumab ...

AEGEAN is a randomised, double-blind ... South America and Asia. Imfinzi (durvalumab) is a human monoclonal antibody that binds to the PD-L1 protein and blocks the interaction of PD-L1 with the PD-1 ...

neoadjuvant chemotherapy alone WILMINGTON, Del., March 31, 2025--(BUSINESS WIRE)--AstraZeneca’s IMFINZI ® (durvalumab) in combination with gemcitabine and cisplatin as neoadjuvant treatment ...

Durvalumab-based perioperative regimen is the first FDA-approved immunotherapy for muscle-invasive bladder cancer (MIBC), showing significant event-free and overall survival benefits in the ...

The US Food and Drug Administration (FDA) has approved a perioperative durvalumab (Imfinzi, AstraZeneca) regimen for adults with muscle-invasive bladder cancer. Specifically, the indication is for ...